Tumor-associated vasculature and liver tumor tissue

Tumor-associated vasculature and liver tumor tissue refers to the anatomical and physiological environment of primary or metastatic liver malignancies, rather than a single molecular entity [1]. This environment is characterized by intense angiogenesis, where the tumor recruits new blood vessels primarily from the hepatic artery to support its rapid growth [1]. This physiological shift from the portal vein supply to the hepatic artery supply allows for the selective delivery of regional therapies such as Transarterial Chemoembolization (TACE) and Selective Internal Radiation Therapy (SIRT) [2]. Molecularly, the vasculature is driven by the over-expression of growth factors like Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF), which are the primary targets of systemic multi-kinase inhibitors [3]. These drugs, such as Sorafenib and Lenvatinib, aim to starve the tumor of oxygen and nutrients by inhibiting signaling pathways essential for endothelial cell proliferation [4]. Additionally, the liver tumor tissue itself is the target for cytotoxic agents and immune checkpoint inhibitors that modulate the local immune microenvironment [5]. While targeting this environment is a cornerstone of Hepatocellular Carcinoma (HCC) management, it presents significant challenges, including the risk of hepatotoxicity and systemic vascular side effects [6].

Other names

Hepatic tumor microenvironmentLiver tumor neovasculatureHCC stroma and vesselsTumor-associated endothelium

Inhibition of pro-angiogenic signaling pathways (VEGF/PDGF/FGF) and localized delivery of cytotoxic or radioactive agents via the hepatic arterial supply.